IL270842B2 - 6-5 fused ring as c5a inhibitors - Google Patents

6-5 fused ring as c5a inhibitors

Info

Publication number
IL270842B2
IL270842B2 IL270842A IL27084219A IL270842B2 IL 270842 B2 IL270842 B2 IL 270842B2 IL 270842 A IL270842 A IL 270842A IL 27084219 A IL27084219 A IL 27084219A IL 270842 B2 IL270842 B2 IL 270842B2
Authority
IL
Israel
Prior art keywords
pct
mmol
compounds
alkyl
found
Prior art date
Application number
IL270842A
Other languages
English (en)
Hebrew (he)
Other versions
IL270842B1 (en
IL270842A (en
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of IL270842A publication Critical patent/IL270842A/en
Publication of IL270842B1 publication Critical patent/IL270842B1/en
Publication of IL270842B2 publication Critical patent/IL270842B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Insulating Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL270842A 2017-05-31 2019-11-21 6-5 fused ring as c5a inhibitors IL270842B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513025P 2017-05-31 2017-05-31
PCT/US2018/034908 WO2018222601A1 (en) 2017-05-31 2018-05-29 5-5 FUSED RINGS AS C5a INHIBITORS

Publications (3)

Publication Number Publication Date
IL270842A IL270842A (en) 2020-01-30
IL270842B1 IL270842B1 (en) 2023-01-01
IL270842B2 true IL270842B2 (en) 2023-05-01

Family

ID=64455572

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270842A IL270842B2 (en) 2017-05-31 2019-11-21 6-5 fused ring as c5a inhibitors

Country Status (15)

Country Link
US (2) US10683294B2 (cg-RX-API-DMAC7.html)
EP (1) EP3630774B1 (cg-RX-API-DMAC7.html)
JP (1) JP7141129B2 (cg-RX-API-DMAC7.html)
KR (1) KR102586710B1 (cg-RX-API-DMAC7.html)
CN (1) CN111032658B (cg-RX-API-DMAC7.html)
AR (1) AR111841A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018277523B2 (cg-RX-API-DMAC7.html)
CA (1) CA3064025A1 (cg-RX-API-DMAC7.html)
ES (1) ES2934507T3 (cg-RX-API-DMAC7.html)
IL (1) IL270842B2 (cg-RX-API-DMAC7.html)
MA (1) MA48800A (cg-RX-API-DMAC7.html)
MX (1) MX391392B (cg-RX-API-DMAC7.html)
TW (1) TWI813570B (cg-RX-API-DMAC7.html)
WO (1) WO2018222601A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201907755B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
KR102852027B1 (ko) 2017-12-22 2025-08-27 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 5,5-융합 고리 화합물
ES2980175T3 (es) * 2017-12-22 2024-09-30 Chemocentryx Inc Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
CN111954525B (zh) * 2018-04-02 2023-12-26 凯莫森特里克斯股份有限公司 稠合双环C5aR拮抗剂的前药
CN114206338B (zh) 2019-07-10 2025-12-12 凯莫森特里克斯股份有限公司 作为pd-l1抑制剂的二氢化茚类
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
PH12022550877A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
EP4219453A4 (en) * 2020-09-28 2024-10-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PYRAZOLE COMPOUND AND ITS PREPARATION METHOD AND ITS USE
JP2023548117A (ja) 2020-10-28 2023-11-15 ケモセントリックス， インコーポレイテッド 化膿性汗腺炎を処置する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214855A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20140051688A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Pyrrolopyrazoles as n-type calcium channel blockers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP5260818B2 (ja) 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
JP4196678B2 (ja) 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
JP2006508894A (ja) 2002-03-28 2006-03-16 ニューロジェン・コーポレーション Ｃ５ａ受容体調節因子としての置換テトラヒドロイソキノリン
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
US20040014782A1 (en) 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004018460A1 (en) 2002-08-21 2004-03-04 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) * 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
CN102131390A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス，インコーポレイティド 可溶性Ｃ５ａＲアンタゴニスト
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
ES2980175T3 (es) 2017-12-22 2024-09-30 Chemocentryx Inc Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
KR102852027B1 (ko) 2017-12-22 2025-08-27 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 5,5-융합 고리 화합물
CN111954525B (zh) 2018-04-02 2023-12-26 凯莫森特里克斯股份有限公司 稠合双环C5aR拮抗剂的前药

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214855A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20140051688A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Pyrrolopyrazoles as n-type calcium channel blockers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WINTERS, MICHAEL P., ET AL., DISCOVERY AND SAR OF NOVEL TETRAHYDROPYRROLO [3, 4-C] PYRAZOLES AS INHIBITORS OF THE N-TYPE CALCIUM CHANNEL., 31 December 2014 (2014-12-31) *

Also Published As

Publication number Publication date
CN111032658A (zh) 2020-04-17
TWI813570B (zh) 2023-09-01
JP2020522483A (ja) 2020-07-30
TW201902897A (zh) 2019-01-16
US20180346471A1 (en) 2018-12-06
AR111841A1 (es) 2019-08-21
MX391392B (es) 2025-03-21
US20210009594A1 (en) 2021-01-14
AU2018277523B2 (en) 2022-06-23
MX2019014292A (es) 2022-04-07
CA3064025A1 (en) 2018-12-06
ES2934507T3 (es) 2023-02-22
EP3630774A4 (en) 2020-10-07
MA48800A (fr) 2020-04-08
BR112019025230A2 (pt) 2020-06-16
CN111032658B (zh) 2022-12-20
KR20200013720A (ko) 2020-02-07
JP7141129B2 (ja) 2022-09-22
KR102586710B1 (ko) 2023-10-10
WO2018222601A1 (en) 2018-12-06
ZA201907755B (en) 2023-05-31
IL270842B1 (en) 2023-01-01
US10683294B2 (en) 2020-06-16
AU2018277523A1 (en) 2019-12-05
IL270842A (en) 2020-01-30
RU2019142985A (ru) 2021-06-30
EP3630774B1 (en) 2022-11-23
US11479553B2 (en) 2022-10-25
EP3630774A1 (en) 2020-04-08
RU2019142985A3 (cg-RX-API-DMAC7.html) 2021-09-03

Similar Documents

Publication Publication Date Title
US11773091B2 (en) 6-5 fused rings as C5a inhibitors
IL270842B2 (en) 6-5 fused ring as c5a inhibitors
AU2018388657B2 (en) Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
IL277608B2 (en) Prodrugs of conjugated c5ar antagonists
CA3064017C (en) 6-5 fused rings as c5a inhibitors
RU2780322C2 (ru) 5-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
RU2780338C2 (ru) 6-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
HK40026719B (en) 5-5 fused rings as c5a inhibitors
HK40026719A (en) 5-5 fused rings as c5a inhibitors
HK40026727A (en) 6-5 fused rings as c5a inhibitors
HK40026727B (en) 6-5 fused rings as c5a inhibitors
BR112019025230B1 (pt) Anéis 5-5 fundidos como inibidores de c5a, seus usos e composição farmacêutica
BR112019025049B1 (pt) Compostos com anéis 6- 5 fundidos e composição farmacêutica que os compreende